The Balearic biotech company Laminar Pharmaceuticals takes its first steps towards alternative financing and the stock markets.
Laminar Pharma has achieved its inclusion as a Pre-Market Environment company in the Growth segment. The company is preparing to enter the stock market by the end of the year, with the aim of accessing new sources of external financing and consolidating its expansion plans.
Biotech companies are expanding and need to diversify their sources of funding for their growth plans, which is why private equity and venture capital (Venture Capital) raises were consolidated last year as the main financing instruments in Spain. The Spanish biotech sector multiplied by 9 the investment raised by private equity, up to 349 MM euros in 2019 according to ASCRI -Spanish Association of Capital, Growth and Investment-.
After two record years, both in terms of volume and number of operations, total private equity investment surpassed its historical maximum in 2019. In view of the good track record of the stock market as an alternative source of financing, the biotech company Laminar Pharma, which was the first spin-off of the University of the Balearic Islands in 2006, has now begun to take its first steps to attract private and institutional investors on the Spanish stock market BME (Bolsas y Mercados Españoles). It does so through the Entorno Pre-Market (EpM) program, designed for SMEs in expansion and with great potential. EpM is a seal of guarantee for investors.
There is a trend of structural change in the non-bank business financing model that will continue in the coming years. Venture Capital and Private Equity formulas have been consolidated as the main financing instruments in Spain. It is relevant to highlight that Spain is the ninth power in scientific production in biotechnology according to the last annual report of the Asebio Association where it is highlighted that the science of the Spanish biotechnology sector is excellent and its patents are becoming more and more international.
Pablo V. Escribá, CEO of Laminar Pharma, states: “We have worked with two management teams of renowned financial advisors such as Fellow Funders and XtartCube to prepare our company’s future strategy. One of our priority objectives is to prepare ourselves well for entry into the continuous market and, as companies that become listed on the stock market must demonstrate a business project adapted to a strict management and control discipline, we wanted to count on the support and guidance of EpM. We are sure that this first step of accessing the alternative stock market – MAB – will offer us an excellent opportunity to make visible our vocation of service to society while giving us the opportunity to invest in a business that works with the sole purpose of improving the quality and life expectancy of people with serious illnesses”.
– – –
For more information: www.laminarpharma.com